Collaborators GBDD. Global, regional, and National burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the global burden of disease study 2021. Lancet. 2023;402(10397):203–34. https://doi.org/10.1016/S0140-6736(23)01301-6.
ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, Collins BS, Hilliard ME, Isaacs D, Johnson EL, Kahan S, Khunti K, Leon J, Lyons SK, Perry ML, Prahalad P, Pratley RE, Seley JJ, Stanton RC, Gabbay RA, on behalf of the American Diabetes A. 2. Classification and diagnosis of diabetes: standards of care in Diabetes-2023. Diabetes Care. 2023;46(Suppl 1):S19–40. https://doi.org/10.2337/dc23-S002.
Antar SA, Ashour NA, Sharaky M, Khattab M, Ashour NA, Zaid RT, Roh EJ, Elkamhawy A, Al-Karmalawy AA. Diabetes mellitus: Classification, mediators, and complications; A gate to identify potential targets for the development of new effective treatments. Biomed Pharmacother. 2023;168:115734. https://doi.org/10.1016/j.biopha.2023.115734.
Gupta S, Dominguez M, Golestaneh L. Diabetic kidney disease: an update. Med Clin North Am. 2023;107(4):689–705. https://doi.org/10.1016/j.mcna.2023.03.004.
Ricciardi CA, Gnudi L. Kidney disease in diabetes: from mechanisms to clinical presentation and treatment strategies. Metabolism. 2021;124:154890. https://doi.org/10.1016/j.metabol.2021.154890.
Selby NM, Taal MW. An updated overview of diabetic nephropathy: Diagnosis, prognosis, treatment goals and latest guidelines. Diabetes Obes Metab. 2020;22(Suppl 1):3–15. https://doi.org/10.1111/dom.14007.
Ali MK, Pearson-Stuttard J, Selvin E, Gregg EW. Interpreting global trends in type 2 diabetes complications and mortality. Diabetologia. 2022;65(1):3–13. https://doi.org/10.1007/s00125-021-05585-2.
Su B, Wang Y, Dong Y, Hu G, Xu Y, Peng X, Wang Q, Zheng X. Trends in diabetes mortality in urban and rural China, 1987–2019: A joinpoint regression analysis. Front Endocrinol (Lausanne). 2021;12:777654. https://doi.org/10.3389/fendo.2021.777654.
Pearson-Stuttard J, Buckley J, Cicek M, Gregg EW. The changing nature of mortality and morbidity in patients with diabetes. Endocrinol Metab Clin North Am. 2021;50(3):357–68. https://doi.org/10.1016/j.ecl.2021.05.001.
Eddy AC, Trask AJ. Growth differentiation factor-15 and its role in diabetes and cardiovascular disease. Cytokine Growth Factor Rev. 2021;57:11–8. https://doi.org/10.1016/j.cytogfr.2020.11.002.
Tang Y, Liu T, Sun S, Peng Y, Huang X, Wang S, Zhou Z. Role and mechanism of growth differentiation factor 15 in chronic kidney disease. J Inflamm Res. 2024;17:2861–71. https://doi.org/10.2147/JIR.S451398.
Lajer M, Jorsal A, Tarnow L, Parving HH, Rossing P. Plasma growth differentiation factor-15 independently predicts all-cause and cardiovascular mortality as well as deterioration of kidney function in type 1 diabetic patients with nephropathy. Diabetes Care. 2010;33(7):1567–72. https://doi.org/10.2337/dc09-2174.
Bidadkosh A, Lambooy SPH, Heerspink HJ, Pena MJ, Henning RH, Buikema H, Deelman LE. Predictive properties of biomarkers GDF-15, NTproBNP, and hs-TnT for morbidity and mortality in patients with type 2 diabetes with nephropathy. Diabetes Care. 2017;40(6):784–92. https://doi.org/10.2337/dc16-2175.
Carlsson AC, Nowak C, Lind L, Ostgren CJ, Nystrom FH, Sundstrom J, Carrero JJ, Riserus U, Ingelsson E, Fall T, Arnlov J. Growth differentiation factor 15 (GDF-15) is a potential biomarker of both diabetic kidney disease and future cardiovascular events in cohorts of individuals with type 2 diabetes: a proteomics approach. Ups J Med Sci. 2020;125(1):37–43. https://doi.org/10.1080/03009734.2019.1696430.
Sen T, Li J, Neuen BL, Arnott C, Neal B, Perkovic V, Mahaffey KW, Shaw W, Canovatchel W, Hansen MK, Heerspink HJL. Association between Circulating GDF-15 and Cardio-Renal outcomes and effect of canagliflozin: results from the CANVAS trial. J Am Heart Assoc. 2021;10(23):e021661. https://doi.org/10.1161/JAHA.121.021661.
Xie S, Li Q, Luk AOY, Lan HY, Chan PKS, Bayes-Genis A, Chan FKL, Fung E. Major adverse cardiovascular events and mortality prediction by Circulating GDF-15 in patients with type 2 diabetes: a systematic review and meta-analysis. Biomolecules. 2022;12(7). https://doi.org/10.3390/biom12070934.
Zeng X, Zhang Y, Kwong JS, Zhang C, Li S, Sun F, Niu Y, Du L. The methodological quality assessment tools for preclinical and clinical studies, systematic review and meta-analysis, and clinical practice guideline: a systematic review. J Evid Based Med. 2015;8(1):2–10. https://doi.org/10.1111/jebm.12141.
Sterne JA, Hernan MA, Reeves BC, Savovic J, Berkman ND, Viswanathan M, Henry D, Altman DG, Ansari MT, Boutron I, Carpenter JR, Chan AW, Churchill R, Deeks JJ, Hrobjartsson A, Kirkham J, Juni P, Loke YK, Pigott TD, Ramsay CR, Regidor D, Rothstein HR, Sandhu L, Santaguida PL, Schunemann HJ, Shea B, Shrier I, Tugwell P, Turner L, Valentine JC, Waddington H, Waters E, Wells GA, Whiting PF, Higgins JP. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919. https://doi.org/10.1136/bmj.i4919.
Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, Savovic J, Schulz KF, Weeks L, Sterne JA, Cochrane Bias Methods G, Statistical Cochrane G. The Cochrane collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928. https://doi.org/10.1136/bmj.d5928.
Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, Norris S, Falck-Ytter Y, Glasziou P, DeBeer H, Jaeschke R, Rind D, Meerpohl J, Dahm P, Schunemann HJ. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011;64(4):383–94. https://doi.org/10.1016/j.jclinepi.2010.04.026.
Frimodt-Moller M, von Scholten BJ, Reinhard H, Jacobsen PK, Hansen TW, Persson FI, Parving HH, Rossing P. Growth differentiation factor-15 and fibroblast growth factor-23 are associated with mortality in type 2 diabetes – An observational follow-up study. PLoS ONE. 2018;13(4):e0196634. https://doi.org/10.1371/journal.pone.0196634.
Januzzi JL, Mohebi R, Liu Y, Sattar N, Heerspink HJL, Tefera E, Vaduganathan M, Butler J, Yavin Y, Li J, Pollock CA, Perkovic V, Neal B, Hansen MK. Cardiorenal Biomarkers, Canagliflozin, and outcomes in diabetic kidney disease: the CREDENCE trial. Circulation. 2023;148(8):651–60. https://doi.org/10.1161/CIRCULATIONAHA.123.065251.
Shora HA, El-Deen IM, El-Lithy NM, Abo-Elmatty DM, Khirallah SM. Growth differentiation factor-15: A marker for diabetic kidney disease in patients with metabolic-associated fatty liver disease. J Diabetes Complications. 2025;39(6):109037. https://doi.org/10.1016/j.jdiacomp.2025.109037.
Gohda T, Kamei N, Tanaka M, Furuhashi M, Sato T, Kubota M, Sanuki M, Koshida T, Hagiwara S, Suzuki Y, Murakoshi M. Association of difference between eGFR from Cystatin C and creatinine and serum GDF-15 with adverse outcomes in diabetes mellitus. J Cachexia Sarcopenia Muscle. 2025;16(4):e70011. https://doi.org/10.1002/jcsm.70011.
Falkowski B, Rogowicz-Frontczak A, Szczepanek-Parulska E, Krygier A, Wrotkowska E, Uruska A, Araszkiewicz A, Ruchala M, Zozulinska-Ziolkiewicz D. Novel biochemical markers of neurovascular complications in type 1 diabetes patients. J Clin Med. 2020;9(1). https://doi.org/10.3390/jcm9010198.
Zhu X, Zhang Y, Liang F, Yin J, Jiang L, Cai W, Lu J, Zhang C, Xiao Y, Teng H, Ge W, Hu Y, Lu Y, Su J, Zhang J, Wu M. Relationship between plasma growth differentiation factor 15 levels and complications of type 2 diabetes mellitus: A Cross-sectional study. Can J Diabetes. 2023;47(2):117–e123117. https://doi.org/10.1016/j.jcjd.2022.09.116.
Zou LX, Hou ZL, Qian CH, Wang X, Sun L. Performance of novel biomarkers for prediction of diabetic kidney disease in patients with diabetes mellitus. Ann Med. 2025;57(1):2562996. https://doi.org/10.1080/07853890.2025.2562996.
Iglesias P, Silvestre RA, Diez JJ. Growth differentiation factor 15 (GDF-15) in endocrinology. Endocrine. 2023;81(3):419–31. https://doi.org/10.1007/s12020-023-03377-9.
Mazagova M, Buikema H, van Buiten A, Duin M, Goris M, Sandovici M, Henning RH, Deelman LE. Genetic deletion of growth differentiation factor 15 augments renal damage in both type 1 and type 2 models of diabetes. Am J Physiol Ren Physiol. 2013;305(9):F1249–1264. https://doi.org/10.1152/ajprenal.00387.2013.
Kim YI, Shin HW, Chun YS, Park JW. CST3 and GDF15 ameliorate renal fibrosis by inhibiting fibroblast growth and activation. Biochem Biophys Res Commun. 2018;500(2):288–95. https://doi.org/10.1016/j.bbrc.2018.04.061.
von Rauchhaupt E, Klaus M, Ribeiro A, Honarpisheh M, Li C, Liu M, Kohler P, Adamowicz K, Schmaderer C, Lindenmeyer M, Steiger S, Anders HJ, Lech M. GDF-15 suppresses puromycin aminonucleoside-Induced podocyte injury by reducing Endoplasmic reticulum stress and glomerular inflammation. Cells. 2024;13(7). https://doi.org/10.3390/cells13070637.
Delrue C, Speeckaert R, Delanghe JR, Speeckaert MM. Growth differentiation factor 15 (GDF-15) in kidney diseases. Adv Clin Chem. 2023;114:1–46. https://doi.org/10.1016/bs.acc.2023.02.003.
Lasaad S, Crambert G. GDF15, an emerging player in renal physiology and pathophysiology. Int J Mol Sci. 2024;25(11). https://doi.org/10.3390/ijms25115956.
Lu Q, Wang WW, Zhang MZ, Ma ZX, Qiu XR, Shen M, Yin XX. ROS induces epithelial-mesenchymal transition via the TGF-beta1/PI3K/Akt/mTOR pathway in diabetic nephropathy. Exp Ther Med. 2019;17(1):835–46. https://doi.org/10.3892/etm.2018.7014.
Tuttle KR, Jones CR, Daratha KB, Koyama AK, Nicholas SB, Alicic RZ, Duru OK, Neumiller JJ, Norris KC, Rios Burrows N, Pavkov ME. Incidence of chronic kidney disease among adults with Diabetes, 2015–2020. N Engl J Med. 2022;387(15):1430–1. https://doi.org/10.1056/NEJMc2207018.
Kaze AD, Jaar BG, Fonarow GC, Echouffo-Tcheugui JB. Diabetic kidney disease and risk of incident stroke among adults with type 2 diabetes. BMC Med. 2022;20(1):127. https://doi.org/10.1186/s12916-022-02317-0.
Koye DN, Magliano DJ, Nelson RG, Pavkov ME. The global epidemiology of diabetes and kidney disease. Adv Chronic Kidney Dis. 2018;25(2):121–32. https://doi.org/10.1053/j.ackd.2017.10.011.
Zhou Z, Liu H, Ju H, Chen H, Jin H, Sun M. Circulating GDF-15 in relation to the progression and prognosis of chronic kidney disease: A systematic review and dose-response meta-analysis. Eur J Intern Med. 2023;110:77–85. https://doi.org/10.1016/j.ejim.2023.01.026.
Li T, Chen Y, Ye T, Zheng L, Chen L, Fan Y, Lin B. Association of growth differentiation factor-15 level with adverse outcomes in patients with stable coronary artery disease: A meta-analysis. Atheroscler Plus. 2022;47:1–7. https://doi.org/10.1016/j.athplu.2021.11.003.
Ma CX, Ma XN, Guan CH, Li YD, Mauricio D, Fu SB. Cardiovascular disease in type 2 diabetes mellitus: progress toward personalized management. Cardiovasc Diabetol. 2022;21(1):74. https://doi.org/10.1186/s12933-022-01516-6.
Teoh IH, Elisaus P, Schofield JD. Cardiovascular risk management in type 1 diabetes. Curr Diab Rep. 2021;21(9):29. https://doi.org/10.1007/s11892-021-01400-9.
Wang D, Day EA, Townsend LK, Djordjevic D, Jorgensen SB, Steinberg GR. GDF15: emerging biology and therapeutic applications for obesity and cardiometabolic disease. Nat Rev Endocrinol. 2021;17(10):592–607. https://doi.org/10.1038/s41574-021-00529-7.
Al-Kuraishy HM, Al-Gareeb AI, Alexiou A, Papadakis M, Nadwa EH, Albogami SM, Alorabi M, Saad HM, Batiha GE. Metformin and growth differentiation factor 15 (GDF15) in type 2 diabetes mellitus: A hidden treasure. J Diabetes. 2022;14(12):806–14. https://doi.org/10.1111/1753-0407.13334.